Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers

Preclinical data suggest that combining a check point inhibition with immunomodulatory derivative can increase anticancer response. We designed a dose escalation study using a 3+3 design to determine the safety, maximum tolerated dose (MTD) or recommended phase 2 dose (R2PD) and dose limiting toxici...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer Ther
Hlavní autoři: Sakamuri, Divya, Glitza, Isabella C., Betancourt Cuellar, Sonia L., Subbiah, Vivek, Fu, Siqing, Tsimberidou, Apostolia M., Wheler, Jennifer J., Hong, David S., Naing, Aung, Falchook, Gerald S., Fanale, Michelle A., Cabanillas, Maria E., Janku, Filip
Médium: Artigo
Jazyk:Inglês
Vydáno: 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935561/
https://ncbi.nlm.nih.gov/pubmed/29237802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0673
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky